New brain cancer drug targets tumors with EGFR mutations
NCT ID NCT06072586
First seen Nov 20, 2025 · Last updated May 01, 2026 · Updated 17 times
Summary
This study tests an experimental drug called BDTX-1535 in people with aggressive brain tumors (high-grade glioma or glioblastoma) that have specific changes in the EGFR gene. The drug is designed to block a growth signal that these tumors rely on. The study has two parts: first, it measures how much drug reaches the tumor during surgery; second, it finds the safest dose to use, possibly combined with standard radiation. About 82 participants will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Chandler Regional Medical Center
RECRUITINGChandler, Arizona, 85224, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
St. Joseph's Hospital and Medical Center
RECRUITINGPhoenix, Arizona, 85013, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.